First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

Published:2016-03-01 Issue:3 Volume:2 Page:305
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Park Keunchil¹,Yu Chong-Jen²,Kim Sang-We³,Lin Meng-Chih⁴,Sriuranpong Virote⁵,Tsai Chun-Ming⁶,Lee Jong-Seok⁷,Kang Jin-Hyoung⁸,Chan K. C. Allen⁹,Perez-Moreno Pablo¹⁰,Button Peter¹¹,Ahn Myung-Ju¹,Mok Tony¹²

Affiliation:

1. Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea

2. Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan

3. Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea

4. Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan 5Chang Gung University College of Medicine, Kaohsiung City, Taiwan

5. Division of Medical Oncology, Chulalongkorn University, Bangkok, Thailand

6. Department of Chest Medicine, Taipei Veteran General Hospital, Taipei, Taiwan8School of Medicine, National Yang-Ming University, Taipei, Taiwan

7. Department of Haematology and Medical Oncology, Seoul National University Bundang Hospital, Bundang, Korea

8. Seoul St Mary’s Hospital, Seoul, Korea

9. Department of Chemical Pathology, Chinese University of Hong Kong, Hong Kong

10. F. Hoffmann–La Roche Ltd, Basel, Switzerland

11. Roche Products Pty Ltd, Dee Why, Australia

12. State Key Laboratory of South China, Hong Kong Cancer Institute, Chinese University of Hong Kong, Sha Tin, Hong Kong

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

2. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population;Future Oncology;2024-06-23

3. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach;Exploration of Targeted Anti-tumor Therapy;2024-05-17

4. Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence;European Respiratory Review;2024-04-30

5. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer;Thoracic Cancer;2024-04-16